The at-risk-to-early continuum of enteropathic spondyloarthritis

The Lancet Rheumatology · Published 2026-06-22 · DOI 10.1016/s2665-9913(26)00087-1

Authors (11)

Francesco Caso, Olga Maria Nardone, Luisa Costa, Nicolò Girolimetto, Mario Cascone, Anna Schettino, Anella Saviano, Raffaele Scarpa, Francesco Maione, Roberto Giacomelli, Piero Ruscitti

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Caso, F., Nardone, O., Costa, L., et al. (2026). The at-risk-to-early continuum of enteropathic spondyloarthritis. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(26)00087-1

Related articles

• Practical Tips for Diagnosis and Management of Concomitant Inflammatory Spondyloarthritis and Inflammatory Bowel Disease · Current Gastroenterology Reports · 2025 · Cites or is cited by this article
• Redefining axial spondyloarthritis: more than just back pain · The Lancet Rheumatology · 2026 · Same journal
• Anti-MDA5-associated rapidly progressive-ILD—the intersection of hyperinflammation and fibrosis · The Lancet Rheumatology · 2026 · Same journal
• Infection risk in adults with secondary HLH · The Lancet Rheumatology · 2026 · Same journal
• Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study · The Lancet Rheumatology · 2026 · Same journal
• Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthritis · The Lancet Rheumatology · 2026 · Same journal
• Prediction of psoriatic arthritis risk: watch for symptoms · The Lancet Rheumatology · 2026 · Same journal
• Lifestyle factors in difficult-to-treat rheumatoid arthritis · The Lancet Rheumatology · 2026 · Same journal
• Research in Brief · The Lancet Rheumatology · 2026 · Same journal
• Gout treat-to-target for whom? · The Lancet Rheumatology · 2026 · Same journal